<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01453933</url>
  </required_header>
  <id_info>
    <org_study_id>RASSTER2010</org_study_id>
    <nct_id>NCT01453933</nct_id>
  </id_info>
  <brief_title>RAltegravir Switch STudy: Effects on Endothelial Recovery</brief_title>
  <acronym>RASSTER</acronym>
  <official_title>Phase IV, Randomized, Open Label, Crossover, Intervention Trial to Investigate the Effect of the Switch of Lopinavir/Ritonavir to Raltegravir on Endothelial Function, Chronic Inflammation, Immune Activation and HIV Replication &lt;50 Copies/ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment with HIV-infection with protease inhibitors is associated with high blood lipids&#xD;
      and higher chance for cardiovascular complications. The RASSTER study aims to investigate the&#xD;
      effect of switching the protease inhibitor lopinavir/ritonavir to raltegravir on vessel wall&#xD;
      function and inflammation,and activation of the immune system. we hypothesize that with this&#xD;
      intervention these parameters will improve. Since decreased vessel wall function and&#xD;
      inflammation are initial steps in the process of atherosclerosis, it is important to know&#xD;
      this data when treating HIV-infected patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fixed dose combination lopinavir/ritonavir (LPV/r) is a widespread used antiretroviral drug&#xD;
      belonging to the class of protease inhibitors (PIs). PIs are associated with an increased&#xD;
      risk of myocardial infarction. However, data is available suggesting increased levels of&#xD;
      plasma lipids are not the sole explanation for this observation. Treatment with LPV/r might&#xD;
      lead to a decrease of endothelial function as well, thus explaining the increased risk of&#xD;
      myocardial infarction besides increased plasma lipids. Raltegravir is a registered&#xD;
      antiretroviral drug with no known cardiovascular side effects. We hypothesize that switching&#xD;
      LPV/r to raltegravir in HIV-infected patients with suppressed plasma viral load (&lt;50&#xD;
      copies/ml) will lead to an improvement of endothelial function.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
        -  First, to assess the effect of the switch of lopinavir/ritonavir to raltegravir on&#xD;
           endothelial function.&#xD;
&#xD;
        -  Second, to assess the effect of the intervention mentioned above on markers of&#xD;
           endothelial function; immune activation; chronic inflammation; and, on plasma HIV-RNA&#xD;
           below the cut-off of 50 copies/ml.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in flow mediated dilatation (FMD) of the brachial artery</measure>
    <time_frame>week 8, week16</time_frame>
    <description>Change in flow-mediated dilatation (FMD) of the brachial artery after 8 weeks of raltegravir treatment as compared to the control group (treatment with lopinavir/ritonavir)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in markers of chronic inflammation</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of immune activation</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of endothelial function</measure>
    <time_frame>Baseline, week 2, week 4, week 8, week 10, week 12 and week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma HIV-RNA below 50 copies/ml</measure>
    <time_frame>Baseline, week 8, week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>HIV Infection</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At baseline, lopinavir-ritonavir will be switched to raltegravir (cross-over after 8 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will continue lopinavir/ritonavir (cross-over after 8 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)</description>
    <arm_group_label>Raltegravir</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Treatment with antiretroviral regimen containing lopinavir/ritonavir for at least the&#xD;
             previous 3 months&#xD;
&#xD;
          -  No other protease inhibitors besides lopinavir/ritonavir in antiretroviral regimen&#xD;
&#xD;
          -  Subjects must have a minimum period of viral suppression (plasma HIV-RNA &lt; 50&#xD;
             copies/ml) of 6 months&#xD;
&#xD;
          -  Subjects will not have a history of virological failure on antiretroviral therapy&#xD;
&#xD;
          -  Results of previous resistance testing allowing replacement of lopinavir/ritonavir by&#xD;
             raltegravir&#xD;
&#xD;
          -  CD4+ cell count &gt; 200 cells/µL&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Raltegravir hypersensitivity&#xD;
&#xD;
          -  Treatment of underlying malignancy&#xD;
&#xD;
          -  Renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Acute or decompensated chronic hepatitis (Child-Pugh score C)&#xD;
&#xD;
          -  Modification of antiretroviral regimen in the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy IM Hoepelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven FL van Lelyveld, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Medical Center Utrecht, The Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven FL van Lelyveld, MD</last_name>
    <email>s.f.l.vanlelyveld@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andy IM Hoepelman, MD, PhD</last_name>
    <email>i.m.hoepelman@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord Holland</state>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido van den Berk, MD, PhD</last_name>
      <email>G.E.L.vandenBerk@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven FL van Lelyveld, MD</last_name>
      <email>s.f.l.vanlelyveld@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Andy IM Hoepelman, MD, PhD</last_name>
      <email>i.m.hoepelman@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Steven FL van Lelyveld, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andy IM Hoepelman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2011</study_first_posted>
  <last_update_submitted>December 17, 2013</last_update_submitted>
  <last_update_submitted_qc>December 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>S.F.L. van Lelyveld</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Anti-Retroviral Agents</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Lopinavir/ritonavir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

